Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,295.00+0.63%ETH$2,476.58+0.47%GOLD$4,221.50+1.55%OIL$91.38-0.12%
Smart Investors Daily
SID Premium
LW

NASDAQ · LWAC

LightWave Acquisition Corp.

Financial Services · Asset Management

$10.35

Up+$0.01 (+0.10%)

Updated Oct 9, 2026, 8:07 PM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
301.95M
P/E ratio
123.82
Dividend yield
0.00%
52-week range
$10.10 – $10.39
Volume
98.71K
Avg. volume
45.3K

Price performance · LWAC

LWAC price history

1M range · 7 trading sessions · Daily adjusted prices

Prices through Oct 1, 2026

LWAC closed at $10.35 after 7 trading sessions, up 0.29% for the selected period.

Last close
$10.35
Period change
+0.29%
Period low
$10.32
Period high
$10.39
Daily close
View OHLC price history
LWAC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 1, 2026$10.35$10.35$10.35$10.3598.71K
Sep 22, 2026$10.3821$10.3821$10.3821$10.3821162
Sep 21, 2026$10.35$10.39$10.35$10.391.61K
Sep 18, 2026$10.33$10.33$10.32$10.33225.62K
Sep 17, 2026$10.325$10.325$10.32$10.32484.82K
Sep 16, 2026$10.32$10.32$10.32$10.3228.63K
Sep 14, 2026$10.35$10.35$10.32$10.322.01K

Latest LWAC news

The latest Smart Investors Daily articles mentioning LWAC.

Stock researchCompany · Overview

LWAC research

Overview

Company profile and research snapshot.

Company profile

LightWave Acquisition Corp is a blank check company.

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Aug 25, 2021

Why Is This SPAC Surging 160% Today?

Shares of Locust Walk Acquisition Corp (NASDAQ: LWAC) are surging higher Wednesday morning after the merger with eFFECTOR Therapeutics was approved. eFFECTOR Therapeutics is focused on selective translation regulation inhibitors to treat cancer. The SPAC merger valued the company at $419 million, including a $60 million PIPE with an investment from Pfizer Inc's (NYSE: PFE) venture capital arm Pfizer Ventures. Related Link: Exclusive: Accelerate CEO On SPAC Arbitrage, Why You Can't Always Bet On SPAC Sponsor Why The Stock Is Soaring: Locust Walk Acquisition raised $175 million in its IPO, selling 17.5 ...

Benzinga · Jun 23, 2021

EXCLUSIVE: eFFECTOR, Locust Walk Acquisition CEOs On SPAC Deal, Drug Pipeline

Clinical-stage biopharmaceutical company eFFECTOR Therapeutics is set to go public via the special purpose acquisition company Locust Walk Acquisition Corp (NASDAQ: LWAC) with an enterprise value of $419 million. Steve Worland, the president and CEO of eFFECTOR, and Chris Ehrlich, CEO of Locust Walk Acquisition Corp., appeared on Benzinga's YouTube show "SPACs Attack" for an exclusive interview Wednesday. eFFECTOR Programs: eFFECTOR focuses on using a new class of oncology drugs known as selective translation regulation inhibitors to treat cancer. eFFECTOR has a global partnership with Pfizer Inc (NYSE: PFE) for the development of inhibitors of eIF4E, which is the company's earliest stage program, Worland told Benzinga. Tomivosertib, which targets non-small cell lung cancer, is in late-stage Phase 2 trials and is the furthest along of eFFECTOR's programs, he said, adding ...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By